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Hereditary hemorrhagic telangiectasia presenting
as portal hypertensionHereditary hemorrhagic telangiectasia (HHT), also known
as OslereWebereRendu syndrome, is a rare genetic
vascular disorder characterized by widespread telangiec-
tases that may involve the skin, mucous membranes of the
nasopharynx, lung, brain, liver, and urinary and gastroin-
testinal tracts [1].
We report here the case of a 25-year-old female who
presented to the emergency department with complaints of
progressive abdominal distension, tarry stool, and hema-
temesis. Laboratory examination showed the following:
white blood cell count, 11,300 cells/uL; hemoglobin, 95 g/
L; platelet count, 1871000 cells/uL; sodium, 131 mmol/L;
potassium, 2.9 mmol/L; C-reactive protein, 59.3 mg/dL;
and albumin, 26.2 g/L. Liver and renal function tests were
normal.
Esophagogastroduodenoscopy revealed multiple esopha-
geal varices with bleeding. Abdominal computed tomography
showed multiple hepatic arteriovenous malformations.
Angiography disclosed multiple instances of huge, compli-
cated right hepatic lobe arterioportal shunting and left
lumbar vascular malformations (Fig. 1). Owing to
a presumptive clinical diagnosis of HHT, we performedFigure 1. Angiography revealed (A) right hepatic lobe arterio
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(c.343e) in exon 4 of the activin-like receptor kinase 1
(ACVRL1; HHT2) gene. There was no abnormality in the
endoglin (ENG; HHT1) gene.
Transarterial embolization (TAE) of the arteriovenous
malformations was performed twice, and an improvement
was seen in the esophageal variceal bleeding. However, the
patient had persistent thrombocytopenia and ascites with
a subsequent poor nutritional status. She died of sepsis 6
months later.
HHT is an autosomal dominant disorder [2]. Clinical
diagnosis of HHT is based on the Curacao criteria: epistaxis,
multiple telangiectases, visceral arteriovenous malforma-
tions, and a first-degree relative with HHT [3]. Definite HHT
is diagnosed if at least three out of four criteria are
present, and probable HHT if two criteria are present. The
presence of only one criterion makes the diagnosis unlikely.
This young female denied any history of spontaneous
epistaxis. Left wrist telangiectasia was confirmed by
previous surgical biopsy. Hepatic and visceral vascular
malformations were confirmed by angiography. There was
no significant family history. We adopted the diagnosis ofportal shunting and (B) left lumbar vascular malformations.
ed.
242 Letter to the Editor“probable” HHT. A genetic study was therefore necessary
for a “definitive” diagnosis.
At least five genetic mutations have been reported to
cause HHT. Mutations in ENG and ACVRL1 account for
approximately 85% of cases [4]. Mutations in SMAD4 have
been detected in approximately 2% of patients with
a syndrome of HHT and juvenile polyposis. Another two
genes, 5q31.3e32 (HHT3) and 7p14 (HHT4), have been
suggested by linkage studies. This patient presented no
mutation in ENG but a deletion mutation in the ALK1
gene.
TAE has been reported for the treatment of vascular
malformations of the liver, and transjugular intrahepatic
portosystemic shunt placement would be warranted in
patients with intractable variceal hemorrhage [5]. The
role of liver transplantation has been debated. Hormone
therapies including estrogen preparation, antiestrogens,
angiogenesis inhibitors, and immunosuppressive agents
are effective in reducing the transfusion requirement
and elevating the hemoglobin level in patients with
recurrent HHT but cannot reverse the pathogenesis of
the disease.
In conclusion, genetic analysis is required for the diag-
nosis of HHT if the clinical presentation arouses suspicions.
Angiography is the gold standard to evaluate the type of
liver vascular malformation. TAE is the treatment directed
at AVMs, but its effect is limited.References
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